Ranbaxy Laboratories and Daiichi Sankyo Company have completed the successful closure of their transformational deal with the execution of the final transfer of the remaining equity shares of the Singh family, in Ranbaxy. Pursuant to this, Daiichi Sankyo has now acquired 63.92 per cent of the equity share capital of Ranbaxy comprising 268,711,323 shares as under:

Daiichi has acquired 92,519,126 equity shares through Open Offer, 129,934,134 shares from Singh family and allotted 46258063 shares on preferential basis.

Takashi Shoda, president & CEO of Daiichi Sankyo said, "We are pleased to announce that all the planned transactions of this landmark deal have been successfully completed. We are determined to work with Ranbaxy to realize sustainable growth."

Malvinder Mohan Singh, CEO & MD, Ranbaxy, said, "We are pleased that the deal has been closed successfully. This puts us well on the path to create a hybrid business model that will unlock the strengths of both companies to bring unprecedented value to all stakeholders."

Ranbaxy earlier had received an amount of Rs 3,585 crore (USD 736 million) from Daiichi Sankyo for the preferential issue of equity shares and warrants. This will be used to further drive the company's growth through organic and inorganic means while also retiring some debt at an appropriate time.

Continuing to operate as an independent & autonomous company, Ranbaxy will work closely with Daiichi Sankyo to explore and optimise the growth opportunities across the pharmaceutical value chain.